



Hyphenated mass spectrometry techniques for assessing 
medication adherence: advantages, challenges, clinical applications 
and future perspectives 
 
Abstract  
Nonadherence to prescribed pharmacotherapy is an understated public health 
problem globally and is costing many patients their chance to return to good health 
and healthcare systems billions. Clinicians need an accurate assessment of 
adherence to medications to aid the clinical decision-making process in the event of 
poor patient progress and to maximize the patient health outcomes from the drug 
therapies prescribed. An overview of indirect and direct methods used to measure 
medication adherence is presented, highlighting the potential for accurate measuring 
of drugs in biological samples using hyphenated mass spectrometry techniques to 
provide healthcare professionals with a reliable evidence base for clinical decision 
making. In this review we summarise published applications of hyphenated mass 
spectrometry techniques for a diverse range of clinical areas demonstrating the rise in 
the use of such direct methods for assessing medication adherence. Although liquid 
chromatography-tandem mass spectrometry methods using plasma, serum and urine 
samples are the most popular, in recent years increased attention has been given to 
liquid chromatography high-resolution mass spectrometry methods and alternative 
biosample matrices including hair, saliva and blood microsamples. The advantages 
and challenges of using hyphenated mass spectrometry techniques to address this 
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List of abbreviations 
ADHD   Attention deficit hyperactivity disorder 
APCI   Atmospheric pressure chemical ionisation 
ART   Antiretroviral therapy 
CVD   Cardiovascular disease 
DBS   Dried blood spot 
EI   Electron impact 
ESI   Electrospray ionisation 
GC   Gas chromatography 
GC-MS  Gas chromatography-mass spectrometry 
HIV   Human immunodeficiency virus 
HRMS  High resolution mass spectrometry 
IT   Ion trap 
LC   Liquid chromatography 
LC-MS  Liquid chromatography-mass spectrometry 
LC-MS/MS  Liquid chromatography-tandem mass spectrometry 
LC-HRMS  Liquid chromatography-high resolution mass spectrometry 
LMIC   Low- and middle-income country 




LOQ   Limit of quantification 
MS   Mass spectrometry 
MS/MS  Tandem mass spectrometry 
m/z   Mass to charge ratio 
PCR   Polymerase chain reaction 
qqq   Triple quadrupole 
TDM   Therapeutic drug monitoring 
ToF   Time of flight 
UHPLC  Ultra-high-pressure liquid chromatography 
VAMS   Volumetric absorptive microsampling 
WHO   World Health Organisation 
 
1. Introduction 
Medicines are the most common intervention in global healthcare and are crucial in 
managing chronic conditions, curing communicable diseases and generally 
maintaining health and preventing illness. Getting the most from medicines is 
becoming increasingly important as people are living longer and are suffering from 
more than one long-term condition and therefore require multiple medications [1]. 
However, according to the World Health Organisation (WHO), only 50% of medicines 
in developed countries are taken as recommended and this figure is reported to be 
lower in low income countries [2]. Failure to take a prescribed medication regimen in 
the way recommended by their healthcare provider is termed “medication 
nonadherence” and is documented to be a worldwide problem of striking magnitude 
[2, 3]. Nonadherence to prescribed medicines results in blood drug levels outside of 




complications and worsening of health for patients. For healthcare services, the cost 
of not taking prescribed medicines correctly are staggering and growing and this 
healthcare problem results in medicines wastage and additional use of scarce 
healthcare resources such as avoidable doctor visits, unnecessary additional 
treatments, laboratory tests and unplanned hospital admissions. In cases of poor 
clinical outcomes the clinician needs to know if the patient has followed the prescribed 
regimen. Improving medication adherence, potentially the most effective route to 
improving the therapeutic benefit of pharmacotherapy and improving clinical 
outcomes, remains a challenge for healthcare systems worldwide. In low- and middle-
income countries (LMIC) high levels of substandard and falsified medicines may 
exacerbate this healthcare problem by giving rise to unintentional nonadherence [4]. 
Currently, there is no “gold standard” method for assessing medication adherence in 
routine clinical practice but a multitude of methods have been explored [1,5,6]. These 
methods have generally been divided into two groups; indirect and direct assessment 
methods. Indirect assessment methods including patient self reports, patient 
questionnaires, pill counts, electronic monitors, prescription refill rates and an 
assessment of the patient’s clinical response are the most commonly used due to their 
simplicity and relative ease of use. However, such indirect methods cannot confirm if 
the patient has taken their medication correctly and are proxy measures of medication 
adherence [7,8]. For instance, pill counts simply confirm the number of tablets 
removed from their original container but cannot confirm if these tablets have been 
consumed by the patient. Furthermore, this method provides no information about the 
time a dose was taken which may be crucial in establishing clinical outcomes [1]. Direct 
assessment methods include direct patient observation, determination of drug or 




the detection of an ingestible medication marker, added to the dosage form, in the 
blood [9]. Direct methods are the most accurate approaches for assessing medication 
adherence but are expensive and sometimes result in “white coat adherence”. Directly 
assessing drug, metabolite or biomarker levels in blood and urine samples provides 
an objective measure but levels may vary due to differences in patient metabolism and 
pharmacogenetics. Due to the ease of collection and non-invasiveness among other 
advantages, hair and saliva biosamples have been explored in medication adherence 
studies [10,11]. For therapeutic drugs there are well documented pharmacokinetic 
relationships between the drug dose given and concentration of the drug in the blood 
stream. Tanna and Lawson [9] discuss the potential for assessing adherence to 
medication by determining drug or metabolite levels in blood microsamples as the 
more suitable approach to ensure the presence of drug(s) within the required 
therapeutic window. This approach was also corroborated by other studies [6,12]. 
Considering the negative impact of medication nonadherence on the patient and 
healthcare providers, the need for more information regarding direct drug or metabolite 
measurements in biosamples cannot be overemphasized. Quantitative data 
confirming the presence of the medication in the patient’s body is evaluated based on 
the anticipated therapeutic window and this information can then be used by the 
clinician to assess adherence, rightness of the prescribed dosage and medication 
suitability. 
The assessment of medication adherence by monitoring drug concentrations in 
biosamples has been performed using immunoassays but it is reported that 
immunoassays can suffer from interferences or metabolite effects, cross-reaction 
problems and there is a likelihood of obtaining a considerable number of false positive 




Furthermore, immunoassay kits may not be applicable to specimens other than those 
identified by the manufacturers and a traditional immunoassay quantifies only one 
target analyte [16]. In some studies immunoassay results were considered 
presumptive until confirmed via gas chromatography-mass spectrometry (GC-MS) 
methods [17]. Peat [18], suggests that with GC-MS confirmation, positive 
immunoassay results seemed to drop by 10% over a ten-year period from 18% to 8% 
further suggesting false positive results with the initial immunoassay tests. These 
limitations of immunoassays have promoted the use of hyphenated mass 
spectrometry (MS) techniques in clinical laboratories for nearly two decades with 
recent applications focused more on “personalised” or “precision” medicine. It is on 
this note that this review explores hyphenated MS techniques as a valuable option in 
the direct assessment of medication adherence for a range of clinical conditions.  This 
review provides insight into the general capabilities of MS for the analyses of 
biosamples for adherence studies and particularly highlights advantages, challenges 
and future prospects of these MS-based techniques in the direct assessment of 
medication adherence for a diverse range of clinical areas. 
 
2. Hyphenated mass spectrometry techniques for assessing medication 
adherence 
Hyphenated mass spectrometry techniques combining chromatography and mass 
spectrometry (MS) have revolutionised the analysis of biosamples for clinical 
applications. In Table 1 the different hyphenated combinations of chromatography and 





 LC-MS (liquid chromatography-mass spectrometry), LC-MS/MS (liquid 
chromatography-tandem mass spectrometry), LC-HRMS (liquid 
chromatography-high resolution mass spectrometry) 
 GC-MS (gas chromatography-mass spectrometry) 
These hyphenated MS techniques provide acceptable specificity towards the target 
analyte by giving a separation capability prior to MS, MS/MS or HRMS detection. For 
the quantification of drugs in complex matrices such as biosamples, for medication 
adherence assessment, the mass spectrometer is an ideal detector providing data 
which is characteristic of the analyte coupled with sensitivity. For liquid samples the 
most commonly used LC is HPLC, however, UHPLC is being increasingly used since 
it uses narrow bore LC columns and offers shorter run times of approximately 2 
minutes. In GC-MS applications the electron impact ionisation process provides 
sufficient energy to both ionise and fragment the molecule(s) under investigation to 
produce a fragmentation pattern from which the molecule could be independently 
identified. This capability is lost in LC-MS systems since the low energy electrospray 
ionisation (ESI) process produces little or no fragment ions [19] and suffers from matrix 
effects. ESI is an effective method for converting target analyte in solution into gas 
phase ions suitable for analysis by the processes of desolvation and ion desorption. 
This is especially good for polar analytes and as can be seen from Table 1 is the most 
popular source used for pharmaceutical bioanalysis. Another ionisation technique that 
is used is atmospheric pressure chemical ionisation (APCI). This uses ion-molecule 
reactions, at atmospheric pressure, to transfer charges originating from the action of 
a corona discharge on a spray of the mobile phase. APCI gives a more selective 




The mass spectrometers used with both GC-MS and LC-MS systems fall into three 
broad categories: low-resolution scanning instruments, tandem MS systems, and 
high-resolution scanning systems. All MS systems measure the mass/charge ratio 
(m/z) of ions of interest and in the simplest form, MS provides some type of a molecular 
fingerprint of the analyte of interest. For a low-resolution scanning MS or linear 
quadrupole, the quadrupole mass filter has a mass range of around 3000 with a 
resolution up to 3000. A major challenge with GC-MS analyses is that all analytes must 
be volatile. Consequently, most clinical assays would require multiple extraction steps 
including chemical derivatization so the analytes are sufficiently volatile for analysis. 
The lengthy sample preparation steps involved in GC-MS analyses, resulting in high 
cost and low throughput, has limited its extensive use in clinical medication adherence 
studies as is evident from Table 1. However, the main advantage of this approach is 
the data-rich fingerprint electron impact mass spectrum for each compound eluting 
from the GC column. These can be compared with international databases and in 
combination with a calibrated retention time will provide the necessary specificity for 
target analyte recognition. LC-MS systems have the advantage that, unlike GC-MS 
systems, it is not necessary to derivatise the samples prior to analysis. Because the 
ionisation is a low-energy process, the most abundant and possibly the only significant 
ion formed is usually the MH+ and so the information-rich fragmentation data is not 
available and therefore these low-resolution scanning MS systems are not sufficiently 
selective. This issue is overcome by low resolution tandem MS systems including triple 
quadrupole (qqq) and ion traps (IT). The tandem MS/MS reproduces the fragmentation 
process by passing only the ions of the pre-selected (MS1) analyte into a collision cell, 
where collision induced fragmentation occurs, and the products of these collisions are 




multiple reaction monitoring (MRM). Before any analysis can be carried out, the 
appropriate m/z values for MS1 and MS2 have to be determined. To do this, target 
drug reference compound is used to determine the appropriate m/z values for MS1 
and MS2. This is done by presetting MS1 to transmit the m/z value of the molecular 
ion and scanning MS2 to identify the m/z values of the resulting fragment ions. Once 
MS1 and MS2 are set accordingly the MS/MS instrument will only respond to that 
specific compound. Ion traps are referred to as “tandem in time” and can operate as 
tandem mass spectrometers by alternating between mass selective and non mass 
selective modes of operation. An alternate approach to molecular specificity is offered 
by the high-resolution mass measurement capabilities of the Time of Flight (ToF) and 
Orbitrap instruments. These high resolution mass spectrometry (HRMS) instruments 
are being increasingly used in quantitative bioanalysis [20]. High resolution implies the 
ability to measure the m/z value accurately to within a few parts per million of the mass 
via a calculation or direct measure of the accurate mass, typically to four decimal 
places of the target analyte. This approach provides an alternative to the MRM 
fragmentation based fingerprint of the target analyte. The ability of the HRMS 
instruments to determine accurate mass means that the level of selectivity from the 
LC component of the analysis can be reduced thus producing a time saving with no 
consequent loss in the value of the results. The data rich information acquired using 
HRMS analyses provides more freedom to analyse for metabolites with small mass 
differences. Further advantages of using an HRMS system include the fact that post 
acquisition data mining is inherent with this approach and all mass spectral information 
from the sample analysed can be recorded in full scan mode and this data covering 
the whole mass range can provide information when monitoring co-eluting interfering 




From Table 1 it is evident that LC-MS based techniques have been widely used for 
the objective assessment of medication adherence in various clinical areas. Due to 
the high sensitivity and specificity, LC-MS/MS has been the main instrument of choice 
for the quantitative determination of therapeutic drugs in biosamples for this healthcare 
application. However, the monopoly of the tandem (MS/MS) system is now being 
challenged by hyphenated HRMS systems with several studies using this approach to 
determine drug concentrations in biosamples to assess adherence to prescribed drug 




Table 1. Hyphenated MS techniques for the quantification of therapeutic drug in medication adherence studies 
Cardiovascular therapy drugs 
Analytical 
Method 
Biosample Analyte(s) Ionisation 
Mode 




DBS Cardiovascular therapy drugs - 
atenolol, atorvastatin, bisoprolol, 
diltiazem, lisinopril, simvastatin, 
valsartan 
ESI LOQ: atenolol 10 ng/ml  
atorvastatin 0.5 ng/ml 
bisoprolol 0.1 ng/ml  
diltiazem 0.5 ng/ml   
lisinopril 0.1 ng/ml   
simvastatin 0.1 ng/ml  




Urine 29 cardiovascular therapy drugs  ESI - [32] 






Antihypertensive drugs - 
amlodipine, canrenone, 
hydrochlorothiazide, metoprolol 
ESI LOQ: amlodipine 0.15 µg/l 
canrenone 8.54 µg/l 
hydrochlorothiazide 0.05 
µg/l 
metoprolol 0.23 µg/l 
[34] 
LC-MS/MS (IT) Serum Antihypertensive drugs ESI - [35] 
LC-HRMS/MS 
(Orbitrap) 






263 prescription and over the 
counter medicines used for 
acute and chronic conditions 
-  - [36] 
GC-MS Urine Antihypertensive drugs - 
ramipril, enalapril, benazepril, 
valsartan, irbesartan, lorsartan, 
metoprolol, bisoprolol, 
propranolol, lercanidipine, 





nitrendipine, verapamil, urapidil, 
torasemid, furosemide, 
piretanid, hydrochlorothiazide, 





Plasma Antihypertensive drugs - 
amlodipine, atenolol, clonidine, 
chlortalidone, doxazosin, 
hydrochlorothiazide, nifedipine, 
olmesartan, ramipril, telmisartan 
ESI LOQ: amlodipine 0.156 
ng/ml 
atenolol 7.812 ng/ml 
clonidine 0.078 ng/ml 
chlortalidone 39.062 ng/ml 
doxazosin 0.078 ng/ml 
hydrochlorothiazide 0.132 
ng/ml 
nifedipine 0.781 ng/ml 
olmesartan 0.781 ng/ml 
ramipril 0.781 ng/ml 








Serum Antihypertensive drugs – 
candesartan, carvedilol, 
diltiazem, enalaprilat, 








ESI LOQ: candesartan 0.55 
ng/ml 
carvedilol 0.51 ng/ml 
diltiazem 0.52 ng/ml 
enalaprilat 0.44 ng/ml 
irbesartan 10.71 ng/ml 
lisonopril 0.24 ng/ml 
ramiprilat 0.19 ng/ml 
valsartan 5.44 ng/ml 
verapamil 0.57 ng/ml 





atenolol 2.66 ng/ml 
bendroflumethiazide 0.11 
ng/ml 
bisoprolol 0.81 ng/ml 
canrenone 0.85 ng/ml 
doxazosin 0.56 ng/ml 
lercanidipine 0.02 ng/ml 
losartan 1.09 ng/ml 
metoprolol 1.3 ng/ml 
nifedipine 3.5 ng/ml 





Serum Antihypertensive drugs - - [41] 
UHPLC-MS/MS Plasma Antihypertensive drugs - 
benazepril hydrochloride, 
fosinopril sodium, captopril, 
hydrochlorothiazide 
- - [42] 




Plasma Antihypertensive drugs - 
amlodipine, lercanidipine, 




-  LOQ: 1.0 ng/ml for all, 
except lercanidipine and 
nebivolol 0.25 ng/ml 








Cardiovascular therapy drugs - 
atenolol, atorvastatin, bisoprolol, 
diltiazem, lisinopril, simvastatin, 
valsartan 
ESI LOQ: atenolol 10 ng/ml 
atorvastatin 0.5 ng/ml 
bisoprolol 0.1 ng/ml  
diltiazem 0.5 ng/ml  
lisinopril 0.1 ng/ml 





valsartan 50 ng/ml 
UHPLC-HRMS 
(ToF) 
DBS Cardiovascular therapy drugs - 
atenolol, atorvastatin, bisoprolol, 
diltiazem, doxazosin, lisinopril, 
losartan, ramipril, simvastatin, 
valsartan 
ESI LOQ: atenolol 10ng/ml  
atorvastatin 0.5ng/ml 
bisoprolol 0.1 ng/ml  
diltiazem 0.5 ng/ml  
doxazosin 0.1 ng/ml  
lisinopril 0.1 ng/ml  
losartan 5 ng/ml  
ramipril 0.1 ng/ml 
simvastatin 0.1 ng/ml  





Urine Antihypertensive drugs - 
amlodipine, atenolol, clonidine, 
chlortalidone, doxazosin, 
hydrochlorothiazide, nifedipine, 
olmesartan, ramipril, telmisartan 
ESI LOQ: amlodipine 7.81 ng/ml 
atenolol 78.12 ng/ml 
clonidine 13.90 ng/ml 
chlortalidone 39.06 ng/ml  
doxazosin 7.81 ng/ml 
hydrochlorothiazide 156.25 
ng/ml 
nifedipine 78.12 ng/ml 
olmesartan 78.12 ng/ml 
ramipril 0.78 ng/ml 






Antihypertensive drugs – 
enalapril, lisinopril, periodopril, 
ramipril, quinalapril, trandolapril, 
candesartan, irbesartan, 
valsartan, losartan, telmisartan, 
olmesartan, atenolol, 
metoprolol, propranolol, 
labetolol, bisoprolol, nebivolol, 
amlodipine, felodipine, 
lercanidipine, lacidipine, 


















Plasma Antihypertensive drugs - 
amlodipine, atenolol, carvedilol, 
clonidine, diltiazem, 
hydrochlorothiazide, 
hydralazine, lisinopril, losartan, 
metoprolol, nifedipine, ramipril, 
valsartan, verapamil 
ESI LOQ: amlodipine 0.5 ng/ml 
atenolol 10 ng/ml 
carvedilol 1 ng/ml 
clonidine 1 ng/ml 
diltiazem 1 ng/ml 
hydrochlorothiazide 5 ng/ml 
hydralazine 25 ng/ml 
lisinopril 5 ng/ml 
losartan 0.5 ng/ml 
metoprolol 1 ng/ml 
nifedipine  1 ng/ml 
ramipril 1 ng/ml 
valsartan 10 ng/ml 






38 medications across broad 
range of chronic diseases 
- - [49] 
UHPLC–MS/MS Plasma Antihypertensive drugs ESI LOQ: amlodipine 0.5 µg/l 
canrenone 1.0 µg/l 
enalapril 0.2 µg/l 
enalaprilate 0.8 µg/l 





losartan 0.5 µg/l 
losartan carboxylic acid 2.0 
µg/l 
nifedipine 4.0 µg/l 
perindopril 0.5 µg/l 
perindoprilate 0.5 µg/l 
spironolactone 2.0 µg/l 
valsartan 5.0 µg/l 
UHPLC-MS/MS 
(qqq) 
Plasma Antihypertensive drugs - 
amlodipine, atenolol, clonidine, 
chlortalidone, doxazosin, 
hydrochlorothiazide, nifedipine, 
olmesartan, ramipril, telmisartan  
ESI LOQ: amlodipine 0.156 
ng/ml 
atenolol 7.812 ng/ml 
clonidine 0.078 ng/ml 
chlortalidone 39.062 ng/ml 
doxazosin 0.078 ng/ml 
hydrochlorothiazide 0.132 
ng/ml 
nifedipine 0.781 ng/ml 
olmesa 0.781 ng/ml 









Antihypertensive drugs – 
enalapril, lisinopril, periodopril, 
ramipril, quinalapril, trandolapril, 
candesartan, irbesartan, 
valsartan, losartan, telmisartan, 
olmesartan, atenolol, 
metoprolol, propranolol, 
labetolol, bisoprolol, nebivolol, 
amlodipine, felodipine, 
lercanidipine, lacidipine, 










ESI - [52] 
UHPLC–MS/MS 
(qqq) 
Urine Antihypertensive drugs - 









lercanidipine, lisinopril, losartan, 
metoprolol, minoxidil, 







piretanide, prazosin, ramipril, 
ramiprilat, spironolactone, 
telmisartan, torasemide, 






Antihypertensive drugs ESI - [25] 
LC-MS/MS 
(qqq) 
Serum Antihypertensive drugs - 
amlodipine, atenolol, bisoprolol, 




lisinopril, losartan, metoprolol, 
perindopril, propranolol, 
quinapril, ramipril, telmisartan 
- 
 
LOQ: 0.7-10 ng/ml [54] 
LC-MS/MS 
(qqq) 
Urine Antihypertensive drugs - - [55] 
LC-HRMS/MS 
(Orbitrap) 
Urine Antihypertensive drugs ESI LOD: 1–20 mg/l [26] 
LC-MS/MS 
(qqq) 




DBS Cardiovascular therapy drugs – 
amlodipine, atenolol, bisoprolol, 
doxazosin, ramipril, simvastatin, 
valsartan 
ESI LOQ: amlodipine 1 ng/ml 
atenolol 25 ng/ml 
bisoprolol 0.5 ng/ml 
doxazosin 1 ng/ml 
ramipril 1 ng/ml 
simvastatin 5 ng/ml 








Urine Antihypertensive drugs – 
enalapril, lisinopril, periodopril, 
ramipril, quinalapril, trandolapril, 
candesartan, irbesartan, 
valsartan, losartan, telmisartan, 
olmesartan, atenolol, 
metoprolol, propranolol, 
labetolol, bisoprolol, nebivolol, 
amlodipine, felodipine, 
lercanidipine, lacidipine, 















Cardiovascular therapy drugs ESI LOQ: 0.2-250 ng/ml [58] 
LC-HRMS (ToF) 
 




DBS Cardiovascular therapy drugs – 





LOQ: bisoprolol 0.5 ng/ml 
ramipril 1 ng/ml 
























Atenolol ESI LOQ: 25 ng/ml [21] 
LC-MS/MS (IT) Serum Antihypertensives - betaxolol, 
metoprolol, bisoprolol, 
amlodipine, nitrendipine, 
verapamil, losartan, telmisartan, 
hydrochlorothiazide, 
chlorthalidone, furosemide, 
doxazosin, rilmenidine, urapidil 
ESI LOQ: 0.5 -1 ng/ml [61] 
Antiretroviral therapy drugs 
LC-MS/MS 
(qqq) 
Hair Zidovudine, efavirenz, ritonavir, 
lopinavir 
APCI LOQ: zidovudine 36 pg/mg 
efavirenz 16 pg/mg 
ritonavir 12 pg/mg 




Plasma Sofosbuvir, sofosbuvir 
metabolite (GS-331007), 
daclatasvir 







DBS Tenofovir, emtricitabine, 
lamivudine  
ESI LOQ: 100 fmol [64] 
LC-MS/MS 
(qqq) 
Hair Tenofovir, lamivudine, 
nevirapine 






Urine Tenofovir, disoproxil 
fumarate/emtricitabine 
APCI LOQ: tenovir  20 ng/ml 




Plasma Efavirenz, lamivudine, 
nevirapine 








Plasma, Hair Antiretroviral therapy drugs - LOQ: 0.31 ng/ml [66] 
LC-MS/MS 
(qqq) 
Plasma Antiretroviral therapy drugs - - [67] 
LC-MS/MS 
(qqq) 
Hair Antiretroviral therapy drugs ESI LOQ: 0.01- 0.05 ng/mg [68] 
LC-MS/MS 
(qqq) 
Hair Antiretroviral therapy drugs ESI LOQ: 0.01- 0.05 ng/mg [69] 
LC-MS/MS Plasma Antiretroviral therapy drugs - - [70] 
LC-MS/MS 
(qqq) 
Hair Antiretroviral therapy drugs ESI LOQ: 0.12 ng/mg [71] 
LC-MS/MS 
(qqq) 







ESI - [73] 
LC-MS/MS 
(qqq) 
Plasma Antiretroviral therapy drugs - - [74] 
LC-MS/MS 
(qqq) 
Plasma Antiretroviral therapy drugs ESI LOQ: 10 ng/ml [75] 
LC-MS/MS 
(qqq) 
Hair Ritonavir, lopinavir, atazanavir  ESI LOD: ritonavir 0.01ng/mg 







Atazanavir, darunavir, efavirenz, 
lopinavir, nevirapine, ritonavir 
ESI LOQ: atazanavir 0.0985 mg/l 
darunavir 0.0500 mg/l 
efavirenz 0.102 mg/l 
lopinavir 0.107 mg/l 
nevirapine 0.101 mg/l 






Antiretroviral therapy drugs ESI LOQ: 41–102 ng/ml [78] 
Pain management drugs 




LC-MS/MS Urine Opioids ESI - [80] 
LC-MS/MS 
(qqq) 










triazolam, venlafaxine, zolpidem 
ESI LOQ: 5.0–50.0 pg/mg [81] 












ESI   LOQ: 2-100 ng/ml [15] 
LC-HRMS (ToF) Urine Opioids, benzodiazepines ESI LOD: 5-500 ng/ml [31] 
LC-MS/MS 
(qqq) 
Serum Opioids - LOQ: 0.2-20 ng/ml [82] 
LC-MS/MS 
(qqq) 











Urine Benzodiazepines ESI LOQ: 50–100 ng/ml [85] 
LC-MS/MS 
(qqq) 
Urine, saliva Opioids ESI LOQ: Saliva - 0.5-25 ng/ml 




Urine Opioids - - [87] 
LC-MS/MS 
(qqq) 
Urine, saliva Opioids, benzodiazepines ESI LOQ: 0.1-25 ng/ml [88] 
LC-MS/MS, LC-
MS, GC-MS 
Urine Opioids - - [89] 
LC-MS/MS 
(qqq) 
Urine Opioids - - [90] 
LC-MS/MS 
(qqq) 
Urine Opioids ESI LOQ: 50 ng/ml [91] 
LC-MS/MS 
(qqq) 
Urine Opioids, benzodiazepines - - [92] 
LC-MS/MS 
(qqq) 











- LOQ: 10-100 ng/ml [93] 
LC-MS/MS 
(qqq) 
Urine Opioids - - [94] 
LC-MS/MS 
(qqq) 






Urine Opioids, benzodiazepines - - [96] 
LC-MS Plasma Opioids - buprenorphine - - [97] 
GC-MS Urine Opioids EI LOD: 50 ng/ml [98] 
GC-MS Urine Opioids 
 
- - [99] 






- LOD: Oxycodone (Free) 100 
µg/l 
Oxycodone (Total) 50 µg/l 
Oxymorphone (Free) - 100 
µg/l 
Oxymorphone (Total)- 50 
µg/l 
Noroxycodone (Free) - 50 
µg/l 
[100] 
GC-MS Urine Benzodiazepines - - [101] 
Type 2 diabetes drugs 
LC-MS/MS 
(qqq) 
Urine Type 2 diabetes drugs ESI - [102] 











ESI - [104] 





Plasma Anastrozole - LOQ: 5-25 ng/ml [106] 
LC-MS/MS 
(qqq) 






Plasma Imatinib - - [108] 
LC-MS/MS 
(qqq) 
Plasma Anastrozole, tamoxifen, 
letrozole 









DBS Creatinine, tacrolimus, 
everolimus, sirolimus, 
cyclosporine A 
ESI LOQ: 1.0 µmol/l [111] 
LC-MS/MS 
(qqq) 
DBS Creatinine, tacrolimus ESI LOQ: 0.01 mg/dl [112] 
LC-MS/MS 
(qqq) 
DBS Cyclosporin A, tacrolimus ESI LOQ: cyclosporin A 8.5 g/l 




Blood Sirolimus, tacrolimus, 
everolimus 




Urine Risperidone, quetiapine, 
olanzapine, haloperidol 
ESI LOQ: risperidone 25 ng/ml 
quetiapine 25 ng/ml 
olanzapine 5 ng/ml 




Serum Risperidone, quetiapine, 
olanzapine, haloperidol 




Urine Amitriptyline, nortriptyline, 
imipramine 
- LOQ: 50 ng/ml [117] 
LC-MS/MS Plasma Citalopram, escitalopram, 
clomipramine 
- LOQ: 10-20 µg/l [118] 
Antiepileptic drugs 
GC-MS DBS, Serum Valproic acid, carbamazepine, 
phenobarbital, phenytoin 













-  [120] 
LC-MS/MS 
(qqq) 
Urine Fluticasone propionate 
 
- LOQ: 10.3 pg/ml [121] 
LC-MS/MS 
(qqq) 






- LOD: 0.03-0.3 g/dl [122] 
LC-MS/MS 
(qqq) 
Urine Fluticasone propionate 
 




Urine Mupirocin ESI LOQ: 5.0 ng/ml [124] 




Serum Moxifloxacin, prothionamide, 
cycloserine 
ESI - [126] 
LC-MS/MS 
(qqq) 




Plasma Methotrexate ESI LOQ: 0.1 nM [128] 
LC-MS/MS 
(qqq) 
DBS Methotrexate polyglutamates ESI LOQ: 5 nmol/l [129] 






Urine 5-aminosalicyclic acid - - [130] 
Attention-deficit/hyperactivity disorder (ADHD) drugs 
LC-MS/MS 
(qqq) 
Oral fluid Lisdexamphetamine ESI LOQ: 7.2 pg/ml [131] 
LC-MS/MS (IT) Hair Lisdexamphetamine - - [132] 
LC-MS/MS 
(qqq) 




3. Biological sample collection 
The collection of a suitable biosample from the patient presents a major challenge in 
the provision of objective drug concentration data using hyphenated MS techniques to 
assess adherence to prescribed pharmacotherapy. Patient age, drug dose, 
pharmacokinetics and the factors affecting the disposition of the drug in the body will 
affect the drug level in the biosample. The sample collection method must be 
acceptable to patients. As can be seen from Table 1, the most frequently used 
biosamples to objectively assess medication adherence are liquid blood (plasma or 
serum) and urine. The shipment costs of these standard matrices are often too high 
and these biosamples require cold storage. Furthermore, the collection of liquid blood 
samples requires a phlebotomist and therefore these factors can be a deterrent for 
widespread acceptance for routine medication adherence monitoring. The collection 
of urine samples is non-invasive and urine can provide a much larger detection window 
than blood samples, however, some patient groups may be reluctant to provide urine 
samples due to religious, cultural or ethical issues [134]. Additionally, 
photodegradation of light sensitive compounds was reported to be much higher in 
urine samples than in whole blood, due to lower turbidity and possible longer exposure 
to daylight [45]. More recently, moves away from urine and whole blood samples have 
been identified. The ease of sample collection, storage and transport provided by 
microsampling methods such as dried blood spot (DBS) cards and volumetric 
absorptive microsampling (VAMS) has seen the increased use of such methods in 
studies to assess medication adherence [21-24, 27, 29, 30, 39, 64, 77, 78, 103, 111-
113, 119, 125, 129]. It is only through the increased sophistication and detection 
capabilities of MS instruments that the micro-volume DBS and VAMS sample can 




has also spurned the investigation of alternate less invasive biosample matrices 
including hair and saliva for assessing medication adherence [10, 11, 62, 66, 68, 69, 
71, 73, 76, 81, 86, 88, 120, 131-133]. The choice of the most appropriate biosample 
would depend on a number of factors including the ease of sample collection from the 
patient and knowing if the available biosample size contains sufficient target analyte 
to be detected. Notional sample volumes and speculative target drug amounts 
contained in these alternative sample formats, based on Cmax and sample volume are 
provided in Table 2. 
 
Table 2. Typical volumes/mass of biological samples [134] 
Sample  Size   Drug mass 
Urine   100-200 ml  0.1-10 µg 
Liquid blood  5-10 ml  10-100 ng 
Saliva   0.5-2 ml  0.1-10 ng 
DBS and VAMS 10-50 µl  1-300 pg 
Hair   20-100 mg  1-300 pg 
Historically, saliva has been less used in medication adherence studies, due to various 
limitations, but the re-emergence of this minimally invasive sampling matrix is probably 
due to the increased MS instrumental detection capabilities coupled with the potential 
in saliva to directly measure the therapeutically active free non-protein bound drug and 
the ease of sampling collection [135, 136]. This sampling matrix was recently 
investigated to assess adherence to antihypertensive drugs where saliva produced 
comparable results to plasma except for acidic drug compounds [11]. 
The evaluation of drug concentrations in hair can provide information about past 




of 1cm per month [137], each segment of hair can be related to a time-period. 
Therefore, drug determination in all hair segments can provide information of an 
average exposure to the drug over the longer term rather than a day-by-day 
assessment. Obtaining a hair sample from a patient is minimally invasive and 
sample(s) do not require cold storage and can be posted to the clinic for use in studies 
to assess medication adherence. From Table 1 it is apparent that novel LC-MS/MS 
assays to determine antiretroviral drug concentrations in hair have been used to 
measure drug adherence in human immunodeficiency virus (HIV) treatment and pre-
exposure prophylaxis [10, 62, 66, 68, 69, 71, 76].  
Although some LC-MS analyses on liquid biosamples can be carried out on samples 
directly using the “dilute-and-shoot” approach, for the majority of biological samples 
some initial sample preparation may be used to aid the analytical process by 
eliminating matrix effects, removing protein and interfering components or to prevent 
excess instrument downtime for column changes and cleaning. Matrix effects are the 
alteration of ionisation efficiency caused by co-eluting constituents such as 
phospholipids and salts. Salts are relatively easy to eliminate whereas phospholipids 
are difficult to remove even with sophisticated sample clean-up procedures. The 
sample clean-up techniques that are available include protein precipitation, liquid-
liquid extraction and solid-phase extraction. The choice of the sample preparation will 
be dependent on the nature of the primary sample and whether an extract should be 
analysed or discarded. A simple sample preparation amenable for the quantitation of 
target analytes in biosamples would facilitate the widespread implementation of LC-
MS-based assays for assessing medication adherence. To prepare a hair sample for 
analysis, hair should be rinsed/decontaminated and divided into sections of known 




the hair structure means that this sample format is not appropriate from a practical 
viewpoint for routine assessment of adherence [134,136]. The sample preparation 
methods for different biological matrices are detailed by Tanna and Lawson [16,134] 
and Capiau et al [138]. 
 
4. Clinical applications of hyphenated mass spectrometry techniques for 
assessing medication adherence  
Nonadherence to medications is documented to be a problem in situations where self-
administration of oral medications is required [1,8]. Self-administration of drug therapy 
is common practice for chronic diseases which include cardiovascular disease (CVD), 
asthma, type 2 diabetes and depression and is also used for oral cancer therapies as 
well as for the treatment of communicable diseases such as HIV, tuberculosis and 
malaria. In order to ensure an effective and efficient treatment plan in which 
therapeutic relief is derived from the prescribed regimen, accuracy in the assessment 
of adherence is crucial [2].  
The analysis of patient biosamples using LC-MS systems for monitoring adherence to 
cardiovascular therapy drugs is escalating as is evident from Table 1. The prevalence 
of non-adherence to cardiovascular therapy drugs is documented to be as high as 
50% [139]. Currently, a combination of cardiovascular therapy medications are 
employed in the treatment of patients with CVD and these include antihypertensives, 
hypolipidemic drugs, anticoagulants and antiplatelet drugs. This low level of 
adherence to prescribed cardiovascular therapies is likely to contribute to poor blood 
pressure control and poor patient outcomes and is considered to be a major problem 




hypertension can be asymptomatic and can exacerbate the problem of nonadherence 
leading to worsening of the chronic problem. This uncontrolled hypertension may 
ultimately lead to adverse outcomes such as stroke, myocardial infarction and kidney 
disease [8,140]. Considering the negative consequences of nonadherence to 
cardiovascular medications, a simple and accurate objective test for direct assessment 
of adherence is crucial to enable clinicians to make an informed decision about the 
patient’s course of treatment. In Table 1 the greatest number of reports objectively 
assessing medication adherence using LC-MS based assays is to cardiovascular 
therapy medicines and this is a pointer to the seriousness of the situation. However, 
assay of cardiovascular drugs in biological fluids has been a challenge for analytical 
scientists. This is as a result of the difficulty in simultaneously determining combined 
cardiovascular therapy drugs belonging to different families with varying 
physicochemical properties in biological fluids. Hyphenated MS techniques offer 
applicability for the analysis of a wide range of drugs and direct assessment of 
adherence to cardiovascular therapy drugs via assays in plasma, serum, urine, saliva, 
DBS and VAMS samples is reported (Table 1). Single measurements of drug levels in 
biosamples may not provide information about the duration of nonadherence or how 
long since the patient took the last dose. Lawson et al. [29] and Tanna et al. [27] report 
the use of self-collected DBS samples to address this issue. Self-collected DBS 
samples at different intervals during dosing were assessed using LC-HRMS for 
determination of CVD therapy drug levels. This approach will allow for detection of any 
pharmacokinetic variations or false negative due to drug-drug interactions. Gupta et al 
[46] show that nonadherent hypertensive patients respond to LC-MS/MS-based 
biochemical analysis with improved adherence to antihypertensives and associated 




should be considered as a potential therapeutic approach to nonadherence-driven 
resistant hypertension. A recent study by Wallbach et al [37] used a GC-MS based 
method for the determination of antihypertensive drugs in urine and found the level of 
nonadherence to antihypertensives to be 58% but a limitation of this GC-MS method 
was that four of the target analytes were detectable only at high concentrations.   
Although HIV infection has no cure, adherence to antiretroviral therapy (ART) is vital 
in order to keep the virus under control by preventing its spread or multiplication which 
could lead to destruction of the immune system. Adherence rates required for optimal 
viral suppression must be at least 95% to achieve optimal viral suppression [141]. 
Although PCR techniques have been widely used to assess adherence to ART drugs 
by measuring the viral load in plasma or DBS once medication has been initiated, as 
can be seen from Table 1 there is a rise in the use of LC-MS/MS assays for the direct 
determination of target ART drug(s). The WHO reports that almost two thirds of the 38 
million people living with HIV globally are based in Africa [142]. Sampling strategy will 
have to take into consideration the socioeconomic situation of the region where 
analysis is to take place and what biosample to be used. Therefore, plasma or serum 
might not be the best option for routine sampling in resource limited settings like sub 
Saharan Africa since trained personnel (phlebotomists) are required for collection of 
samples in clinics or hospitals. There is also the challenge with carrying out venous 
sampling in certain populations like paediatric patients. To address these issues, other 
more patient-friendly sampling methods such as saliva, hair and DBS have been 
investigated for ART therapy adherence assessment [10, 62, 64, 66, 68, 69, 71, 73, 
76-78].  
As is evident from Table 1 another growing area where hyphenated MS techniques 




drugs. Adherence monitoring of pain management medication is crucial especially 
when dealing with chronic non-malignant pain conditions. Current challenges 
confronting the clinician in this regard include abuse, overuse and diversion of 
controlled prescription drugs which include benzodiazepines and opioids [143]. Urine 
is the biological sample commonly used for these analyses as is evident from Table 
1. Urine is preferred for these assays because it provides a long detection window due 
to the drug metabolite pharmacokinetics. A few studies have used plasma, serum, 
saliva and hair for assessing adherence to pain management drugs although drugs 
which are strongly protein bound (e.g. benzodiazepines) generally do not appear in 
high concentrations in saliva [81, 82, 86, 88, 97, 144]. Immunoassays are used for 
screening (qualitative) purposes which may identify drugs but with variable specificity. 
A major limitation of immunoassays for drug quantification is poor sensitivity compared 
to MS based methods. This is demonstrated by Mikel et al [96] who compared a urine 
opiate immunoassay to an LC-MS/MS assay and found that the immunoassay has a 
limit of detection of 300 ng/ml while the LC-MS/MS assay had a limit of detection of 50 
ng/ml which resulted in approximately 69% of patients who were prescribed and taking 
an opiate having detectable drug concentrations from the LC-MS/MS assay but tested 
negative on the immunoassay. Hyphenated MS-based techniques (GC-MS, LC-
MS/MS, LC-HRMS (ToF)) also offer more targeted (quantitative) confirmations. The 
LC-MS/MS has replaced the GC-MS for this analysis since it simplifies the sampling 
process by eliminating the chemical derivatization step in GC-MS.  
Surprisingly very few reports have addressed the assessment of adherence to oral 
hypoglycaemic drugs in the management of Type 2 diabetes via direct MS-based 
bioanalytical assays. A very recent study [102] used an LC-MS/MS (qqq) based urine 




antihypertensive and/or lipid lowering medications. It is postulated that the paucity of 
data related to monitoring adherence to hypoglycaemic drugs may be because blood 
glucose levels are also routinely monitored by diabetic patients using simple 
fingerprick tests [1]. Notwithstanding, objectively monitoring adherence is paramount 
in order to improve clinical outcomes of this chronic illness.  
The widespread problem of medication nonadherence has fuelled interest in the 
application of hyphenated MS-based (predominantly LC-MS/MS (qqq)) bioanalytical 
assays to adherence assessment studies in other clinical areas including cancer in 
situations where oral chemotherapy drugs are prescribed [103-110], 
immunosuppressant therapy [111-114], schizophrenia [115-116], depression [117-
118], epilepsy [119], asthma [120-123], infectious diseases [124, 125],  tuberculosis 
[126, 127], arthritis [128, 129], inflammatory bowel disease [130] and attention deficit 
hyperactivity disorder (ADHD) [131-133].  
Even in the wealthy/industrialised countries where access to the most advanced 
instrumentation is not a major problem, healthcare costs are such that only medication 
adherence assessments for major chronic diseases such as cardiovascular disease 
are likely to be given priority. Infectious diseases like HIV and malaria are a global 
issue but pose a much bigger problem in countries where healthcare facilities are 
limited and so reliance on simpler manual methods would be expected. Collaboration 
between countries such that equipment or biological samples are sent to other 
countries for analysis might be the way forward in addressing the challenge of limited 
access to facilities in some countries and indeed this research group is currently 
collaborating with two of the largest hospitals in Nairobi, Kenya to address the problem 
of non-adherence to cardiovascular medicines since chronic diseases such as 





5. Advantages and challenges of using hyphenated mass spectrometry 
techniques for assessing medication adherence 
Advances in MS technologies have revolutionised the analysis of biosamples for 
clinical studies and marked improvements in analytical specificity and sensitivity have 
augmented the use of hyphenated MS systems for objectively assessing medication 
adherence. Cost reduction has been another factor fuelling the potential use of MS for 
such routine clinical analyses. It can be argued that the initial capital cost of MS-based 
equipment is high, with skilled personnel needed for development, validation and 
application of the bioanalytical assays. However, Jannetto and Fitzgerald [17] suggest 
that MS-based systems can still be cost effective if laboratories develop in-house MS 
tests which will cut down on send-out costs for higher-volume tests. A major advantage 
of using MS-based systems is that it is possible to have a single MS method for a 
multianalyte assay thus saving time, effort and reagents. Simplifying and standardising 
sample processing makes MS-based methods even more appealing to smaller 
laboratories with less expertise especially in LMIC. Another advantage of using MS 
based techniques is that they are commonly used techniques across the world for a 
range of applications and this means they are well understood in terms of limitations 
and their applicability. The potential to provide medication adherence assessment 
tests for a wide range of clinical areas using MS-based techniques is evident from 
Table 1. 
Although advancements with MS-based techniques have made them more attractive 
for potential use in routine clinical analysis, some substantial challenges have to be 




medication adherence. These challenges include the need for skilled personnel, high 
cost of equipment and lack of automation, software and data handling and limitations 
on sample throughput [17,145,146].  
The need for skilled personnel for MS instrument maintenance and running is 
paramount when using MS methods. While front end cleaning is required for all MS 
instruments, HRMS instruments need to be regularly calibrated to maintain the high 
mass accuracy and resolution. A certain level of expertise is required in the method 
development and validation process for bioanalytical applications. Generally, this skill 
set requires training and practical experience on the equipment for a substantial 
amount of time (months to years) to become proficient.  
High initial capital cost of MS systems is another challenge that needs to be addressed 
to facilitate their use in the routine assessment of medication adherence especially in 
global regions were funds are scarce such as in LMIC. Cost is a significant challenge 
in obtaining LC-HRMS instruments for routine clinical applications. The price of an LC-
HRMS instrument is often twice or more compared to a triple quadrupole (qqq) or 
single quadrupole instruments. From Table 1, it is evident that HRMS instruments are 
being used in clinical investigations for assessing medication adherence suggesting 
that their quantitative performance coupled with high specificity is acceptable for such 
analyses. If the costs of the LC-HRMS instruments could be reduced in the future then 
this could bring a shift of paradigm in LC-MS analyses because HRMS gives the most 
complete picture of what is in a biosample. This is very useful in medication adherence 
monitoring studies since the acquired HRMS data can be mined retrospectively to look 
for non-target analytes such as drug metabolites in instances where questionable 
results are obtained initially [29]. Versatility, excellent qualitative and quantitative 




instruments. Working out return on investment might be a way of addressing this 
challenge bearing in mind factors like labour and training costs, service contracts, 
supplies, proficiency testing, time needed for development and validation of the 
method in addition to the cost of equipment. The quality and the amount of data 
required will help justify the use of MS for assessment of medication adherence. In 
LMICs where resources are limited, the approach might be to have these MS-based 
systems in zonal or national laboratories where biosamples from around the regions 
can be sent for analysis. In this situation, the feasibility and costs of transporting the 
biosamples will have to be considered as well. 
The lack of an automated system that incorporates sample processing and preparation 
with the instrumentation is also a challenge especially when dealing with a large 
number of samples. This is usually the case when assessing medication adherence in 
patients taking multiple medications (polypharmacy). Typically, targeted quantitative 
LC-MS/MS analyses using gradient elution are carried out at a rate of a few minutes 
per injection and this can be reduced to about 2 minutes per injection using a UHPLC 
system. These runtimes can limit throughput and therefore developments are required 
to reduce run times more akin to that of direct injection methods but which include 
efficient chromatographic separation of target analytes and matrix components. 
Velghe et al [147] suggest multiplexing as an efficient option for further increasing 
throughput where multiple LC systems are coupled to one MS while ensuring the MS 
is used economically. Advances have also been made in the automation of processes 
related to therapeutic drug monitoring (TDM) which can be applied in the objective 
assessment of medication adherence. For instance, when DBS are employed, semi-
automated punching devices are now available to replace the laborious manual 




handling systems [148] while fully automated DBS analysers that can be coupled to 
standard LC-MS/MS systems are now commercially available [147]. 
Data file storage can also be a major challenge particularly when using LC-HRMS in 
full scan mode for large numbers of samples and data compression can address some 
of these concerns. 
Managing data flow for clinical mass spectrometry testing can be challenging because 
of the lack of automated commercial solutions and data processing, analysis and 
reporting can be a time consuming part of LC-MS-based testing when quantitative 
data is required even for low volume clinical laboratories. It is therefore important to 
implement simplified, robust and optimised workflows for managing mass 
spectrometry data which begins with an order for a laboratory test and ends with an 
uploaded patient result. 
Since the choice of instrumentation is dependent on the analyte of interest, another 
challenge will be deciding what instrument to purchase. The LC-triple-quadrupole 
mass spectrometer (qqq) has been identified as the instrument of choice for small 




Improving medication adherence, potentially the most effective route to improving the 
therapeutic benefit of pharmacotherapy, remains a challenge for healthcare systems 
worldwide. As can be seen from Table 1, researchers and healthcare professionals 




analysis of biosamples in a wide range of clinical areas to address this global 
healthcare problem. The results of such tests will provide the evidence base to aid the 
clinical decision making process and to maximise patient benefit from the prescribed 
drug therapies. These objective results could make a step change in allowing clinician-
patient discussions to be focussed around which treatments are being taken, which 
not and for what reasons. Home or remote sampling will ease the burden on 
overstretched healthcare facilities globally and will augment this process. Assessing 
adherence to prescribed cardiovascular therapy drugs using hyphenated MS-based 
techniques is the fastest growing clinical area which is not surprising given that CVD 
is one of the biggest killers worldwide.  
Analysts face challenges of assay robustness, reproducibility, specificity, sensitivity 
and accuracy of drug quantification and therefore optimisation of biosample, sample 
preparation, mass spectrometry method, LC and MS conditions is required for 
application in a clinical setting. The limitations of immunoassays promote the triple 
quadrupole LC-MS/MS systems as the current best technique for this application as it 
is a more robust and reliable method with superior specificity and sensitivity. LC-
HRMS systems have great potential for quantitative bioanalysis and furthermore 
provide the most complete picture of what is in a biosample and have the inherent 
advantage of post-acquisition data mining. Healthcare providers face numerous 
challenges including instrument costs, instrument complexity, shortage of suitably 
trained staff, software and data handling and limitations on sample throughput in order 
to implement these adherence assessment methods in a wide clinical setting. 
An appropriate analytical method for monitoring medication adherence should be one 
which is able to provide the required data with relative ease and simplicity. The 




the use of microfluidic technology [150] to monitor therapeutic drugs in biosamples will 
go a long way in providing more portable, easy-to-use equipment which will facilitate 
point-of-care assessment of medication adherence. Due to their portability and 
simplicity, these systems could then be used in various settings like clinician offices. 
Commercial availability of more approved MS-based kits, quality controls and 
calibrators is key in the drive towards adopting MS-based methods for routine 
monitoring of medication adherence. Further improvements in specificity and 
sensitivity as well as automation of various processes will make MS-based systems 
even more attractive for routine clinical use. With growth and advancement in 
technology, it is envisaged that hyphenated MS systems will become an essential 
component of clinical medicine for adherence assessment. 
In conclusion, effective adherence to prescribed medications, for an individual, will be 
confirmed if the measured biosample drug levels are within the drug therapeutic 
windows. Thus the analysis of biosamples using hyphenated MS techniques is the 
way forward and will facilitate evidence-based and personalised therapy for the benefit 
of patients globally. The current moves to improve the objective assessment of the 
attainment of therapeutic levels of drugs by increasing adherence must continue and 
the benefits including the personalisation of healthcare, made obvious to all 
stakeholders. 
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In Memoriam: Dr Graham Lawson 
Dr Graham Lawson sadly passed away on September 2nd 2019 and had co-authored 
this Review whilst he was in hospital. Graham was a pioneer in the mass spectrometry 
field and a well-respected analytical chemist internationally, whose significant 
contributions to the instrumental analysis field helped to advance the area in multiple 
ways.  
Graham’s insight was invaluable and he was a very passionate and enthusiastic 
researcher and a dedicated teacher with high standards and principles. He had 
conducted research in disparate areas such as environmental exposure in the polymer 
industry, the identification of migrants from food packaging and factors influencing 
drug delivery and clinical applications and he was also co-opted onto a NATO special 
studies group on standoff detection of radiation. More recently he had conducted 
research into novel analytical techniques applied to dried blood spot analyses for 
healthcare applications and to counterfeit drug detection. 
Graham was a role model and a true example to many, both scientifically but also on 
a personal level. He will be remembered with gratitude and respect for being an 
immensely kind, generous and helpful person and a loyal friend, colleague and 
mentor. Over the years Graham guided, influenced and inspired thousands of 
students, colleagues and others he reached and his legacy will live on through the 
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